BACKGROUND-Repetitive transcranial magnetic stimulation (rTMS) is emerging as a valuable therapeutic and diagnostic tool. rTMS appears particularly promising for disorders characterized by positive sensory phenomena attributable to alterations in sensory cortex excitability. Among these are tinnitus, auditory and visual hallucinations, and pain syndromes.
Introduction
Repetitive transcranial magnetic stimulation (rTMS), a well-tolerated method for focal modulation of cortical excitability, is emerging as a therapeutic tool for a variety of neurologic conditions (1) (2) (3) (4) . In experimental protocols, rTMS can also be used to study cortical plasticity in healthy and disease states (1) (2) (3) (4) (5) (6) (7) . Although rTMS modulatory mechanisms are not completely known, the durable functional changes induced by lowfrequency (≤1Hz; LF rTMS) or high-frequency rTMS (≥10Hz; HF rTMS) resemble those of long-term depression (LTD) and long-term potentiation (LTD) respectively (8) (9) (10) (11) . Additionally, patterned rTMS delivered as either continuous or intermittent bursts of high frequency trains, such as theta burst stimulation (TBS), can also induce LTD-like or LTPlike changes in regional cortical excitability (12) .
Therapeutic rTMS might be particularly beneficial for patients with disorders of regional cortical excitability (13) (14) (15) (16) (17) . Epilepsy is one such example where LF rTMS has been applied over a cortical seizure focus to suppress seizures (18) (19) (20) (21) . Another broad category of disorders are those characterized by positive sensory phenomena that may involve pathologic activation of sensorimotor cortical areas along with related cerebral networks. Among these are tinnitus, auditory hallucinations (AH), visual hallucinations (VH), and pain syndromes such as somatic pain, visceral pain, migraine, and fibromyalgia. -all syndromes where functional imaging data show excess regional sensory cortex activity (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) .
In some of these disorders, cortical hyperactivity may be directly attributable to cortical deafferentation, resulting in disinhibition of excitatory cortical connections. Among these are phantom limb pain, tinnitus, and the VH associated with Charles Bonnet Syndrome (CBS) (37) (38) (39) . In others, such as AH in schizophrenia, migraine or fibromyalgia, the anatomy of aberrant regional cortical activity is less clear. However, functional imaging data in these disorders support excess sensorimotor cortex activation (24, 33, 35, 36, 40) and a number of studies have been aimed to test whether rTMS can interfere with symptom physiology by altering activity in hyperactive cortex. (41) (42) (43) Although rTMS is generally safe when following guidelines, seizure induction remains the most serious safety concern (44) (45) (46) . Analogous to the risks of rTMS in epilepsy (46), such concern is warranted with positive sensory symptoms where stimulation targets may be excessively excitable at baseline. While the assumption that hyperactivity corresponds to hyperexcitability and lowered threshold for seizure and other adverse events remains to be verified, the potential for excess risk in this patient population warrants consideration. Accordingly, we assess the available published data regarding seizures, symptom exacerbation or other adverse events when rTMS is applied over a sensori-motor cortex in chronic pain syndromes as well as in AH, VH, and tinnitus.
Methods

Literature Review
Using PubMed, we reviewed publications from January 1985 to April 2011 using the following keywords: "TMS," "transcranial magnetic stimulation," "rTMS," "repetitive transcranial magnetic stimulation," "auditory hallucinations," "visual hallucinations,"
Results
Literature Review
Subject characteristics, rTMS protocols and outcomes per publication are summarized in Tables 1-7 . For the present analysis we distinguish between tinnitus, AH, neuropathic pain, visceral pain, migraine, fibromyalgia, and VH cases. Of 106 publications (n s (n of subjects) = 1815) identified by literature review, there were 38 publications (n s = 393) related to AH, 37 publications (n s = 877 subjects) related to tinnitus, 18 publications (n s = 311) related to neuropathic pain, five publications (n s = 165) where rTMS was applied to patients with migraine, four publications (n s = 53) address fibromyalgia, two publications (n s = 14) concerning visceral pain, and two publications (n s = 2) describing rTMS in patients with VH. One publication (71) was counted for tinnitus and AH, due to its inclusion of patients with both symptoms.
A total of 101 studies (n s = 1653) described rTMS intensity as a percentage of motor threshold (MT), while six (n s = 181) utilized only a specific machine output (MO). There were two publications (n s = 103) in which a measure of rTMS intensity was not reported. Of AH studies, 11 (n s = 86) used rTMS at or above MT (≥ MT; range 100-120%), and 26 (n s = 306) utilized rTMS at sub-MT levels (< MT; range 80-90%). In one publication (76;n s = 1) rTMS intensity was not described. For the studies involving tinnitus, 29 (n s = 454) used rTMS with ≥MT intensity, while nine (n s = 417) made use of rTMS with <MT intensity, and there were two publications (n s = 128) in which percent of MT was not given, rather stimulation was fixed at 50% MO. Of studies on neuropathic pain six (n s = 38) used rTMS with ≥MT intensity, and 12 (n s = 273) used rTMS with <MT intensity. Two studies describing rTMS in migraine (n s = 15) used ≥MT intensity, one (n s = 6) used <MT intensity, one (n s = 42) used a fixed MO of 30 or 50%, and one (98;n s = 102) did not state the intensity at which rTMS was performed. Fibromyalgia studies had 2 publications (n s = 18), which used ≥MT intensity, and two publications (n s = 35), which used <MT intensity. The two studies on visceral pain had one (n s = 5) which used <MT intensity, and the second (n s = 9) utilized a set 70% MO. For two VH studies (n s = 2), rTMS intensity was 80% MO, and involved two subjects.
There were 77 publications (n s = 1202) using low frequency (LF; ≤1 Hz) protocols, 39 publications using a high frequency (HF; >1Hz) protocol (n s = 804), and three publications using combined LF and HF rTMS (n s = 177). Based upon stimulation paradigm, these studies were binned to both LF and HF or classified as combined.
Thirty-five publications (n s = 373) on AH made use of LF and four studies (n s = 21) utilized HF. For tinnitus, 28 studies (n s = 584) used LF rTMS and 13 studies (n s = 433) used HF alone, while three studies (n s = 177) used HF in combination with LF rTMS. Within those studies involving neuropathic pain, five (n s = 54) utilized LF rTMS, while 17 (n s = 302) used HF rTMS. Migraine publications had three studies (n s = 157) that used LF rTMS, and two (n s = 8) studies that used HF rTMS. Published reports for fibromyalgia had two studies (n s = 18) using LF rTMS, and two studies (n s = 35) using HF rTMS. Visceral pain reports had two studies (n s = 14) with LF rTMS and one (n s = 5) with HF rTMS. Both studies (n s = 2) concerned with VH used LF rTMS at 1 Hz.
Sixty-five studies reported the incidence of adverse events. Of 1815 subjects receiving stimulation, across all 106 publications reviewed, the reported adverse events and numbers of patients are listed in Table 9 . There were eight studies where adverse events were described, yet were not quantified in terms of number of patients. (16, 75, 77, 100, 103, 110, 128, 129) . Finally, there were 38 studies where adverse events were not reported (Tables 1-7) .
Of 106 publications, 39 did not include placebo or sham stimulation (Tables 1-7) . The remaining 67 studies included sham rTMS as part of either a cross-over or a group comparison design.
Risk Assessment
For purposes of analysis, we sorted adverse rTMS-related events into five categories as follows: (1) seizure induction, (2) other serious adverse events, (3) symptom exacerbation, (4) mild adverse events, and (5) no adverse events. Analysis of specific adverse events, categorized by separate positive sensory symptoms, is detailed in Table 9 . a) Seizure induction-Seizures during rTMS were documented in three of 1815 patients (Table 8 ): in one patient with tinnitus after 1 Hz rTMS over left primary auditory cortex (111), and in two with complex regional pain syndrome (CRPS) after 10 Hz rTMS over motor area (113, 122) . This approximates a 0.16% (95% CI: 0 -0.19%) crude risk per subject. The seizure in a tinnitus patient was one in 877 subjects undergoing rTMS, translating to a 0.11% (95% CI: 0 -0.22%) crude per subject risk of seizure during rTMS for tinnitus. Considering the risk of seizure induction according to rTMS frequency within tinnitus subjects: zero out of 477 patients had a seizure induced by HF rTMS while one out of 584 patients had a seizure induced by LF rTMS. These equate a 0.17% (95% CI: 0 -0.33%) crude risk for LF rTMS in patients with tinnitus. The other two seizures occurred in two out of 311 patients with chronic pain giving a 0.64% (95% CI: 0 -0.89%) crude risk. Both seizures were induced by HF-rTMS, equating to a 0.66% (95% CI: 0 -0.92%) crude risk. None of the 54 patients with neuropathic pain undergoing LF rTMS had a seizure.
In all three patients, there was no previous history of seizure. One patient (122) had surgical neurovascular decompression by supraclavicular approach for thoracic outlet syndrome, while the other two patients had otherwise unremarkable medical histories. Only one patient was on medication at the time (113), which consisted of an antidepressant (amitriptyline) and an anticonvulsant (carbamazepine). In all three cases, a generalized seizure occurred with post-ictal confusion. Follow-up did not indicate changes in EEG, MRI, or any motor deficits.
b) Other serious adverse events-In one study (13) , a patient was removed from the study because of ischemic chest pain. The authors note that this individual had a history of hypertension, smoking, and diabetes mellitus, and thus assumed that rTMS did not play a causal role in the ischemic event.
One incidence of optic neuritis was described (98) during a study aimed to test LF rTMS in migraine treatment. The event arose before the treatment with TMS, and was thought by the authors to also not be a result of the treatment. c) Aggravation of sensory symptoms-Aggravation of underlying sensory symptoms was reported in 28 out of 1815 subjects across all studies. The crude risk per subject of symptom aggravation was 1.54% (95% CI: 0.97 -2.11%). When categorized by underlying diagnosis, we found that in the tinnitus group 19 out of 877 patients had a worsening of symptoms, which gives a 2.17% (95% CI: 1.21 -3.13%) crude risk. There were 11 patients out of 584 for LF rTMS, seven out of 433 patients for HF rTMS, and one out of 177 patients with combined HF and LF rTMS who experienced an increase in tinnitus. Symptom aggravation in AH occurred in four out of 39 subjects, which equates to a crude risk of 1.02% (95% CI: 0.03 -2.01%). The crude risk per subject for aggravated tinnitus by LF rTMS is 1.88% (95% CI: 0.78 -2.98%), with HF rTMS it is 1.61% (96% CI: 0 -2.8%), and the combination of HF and LF rTMS gives 0.56% (96% CI: 0 -1.66%). Four out of 373 patients reported aggravated AH with LF rTMS and zero out of 21 patients who were treated with HF rTMS. Crude risk per subject for aggravated AH was 1.07% (95% CI: 0.03 -2.11%) using LF rTMS and 0% for HF rTMS. Last, among patients with migraine there were three out of 165 who had an aggravation of migraine including both headache and aura, equating to a 1.81% (95% CI: 0 -3.85%) crude risk. If the data are restricted only to those patients who were treated with LF rTMS, then aggravation of migraine occurred in three out of 157 patients or a 1.91% (95% CI: 0 -4.05%) crude risk.
Only studies involving tinnitus, AH, and migraine reported symptom aggravation either following or during stimulation. Two studies (13, 76 ; n s = 23 and n s = 1, respectively), reported an increase of AH from baseline during rTMS in four patients with LF rTMS. In one study (13) , increase in AH after stimulation of the temporo-parietal cortex was divided into one reported case for active-blind rTMS and two reported instances for active non-blind rTMS. Duration and level of AH aggravation was not detailed. The case report (76), describes a single patient experiencing an increase in AH for one month, described as "tolerable," following the final LF rTMS session to the left tempoparietal cortex (LTC).
For tinnitus studies, there were 19 patients, 11 receiving LF rTMS, seven receiving HF rTMS, and one who received combined HF and LF rTMS, who experienced tinnitus exacerbation. We note that symptom exacerbation in patients with tinnitus undergoing rTMS requires a specialized definition, as even patients who improved after treatment have experienced transient tinnitus worsening. For instance one study (125) reported that "most" patients in this study experienced a 2-3 day increase in tinnitus symptoms, followed by a clinical improvement afterward. We have chosen to include all instances of aggravated tinnitus, as even in reports where some patients tolerated this increase there were others who exited the study (47).
The authors of one LF rTMS tinnitus study (62; n s = 3) reported a single patient with worsening tinnitus after the first two days of 1 Hz rTMS over auditory cortex (AC). Following this transient increase, the patient had a reduction of tinnitus sensations for 1 week. One other patient (89; n s = 1) had a similar experience in which tinnitus after 1 Hz to the AC increased for two days and then led to a significant reduction. In one LF rTMS study (118; n s = 9) one patient reported an increase in tinnitus volume after only five minutes of stimulation to an area of increased PET signal. The patient returned to their baseline tinnitus volume after resting for five minutes. LF rTMS in this patient was discontinued. Two patients (90; n s = 28) reported a mild increase in tinnitus during 1 Hz rTMS which was performed for 33 minutes per day for 10 days.
Two patients dropped out of their active rTMS trials to the LTC or AC (125; n s = 16) after a two to three day increase in tinnitus. Their tinnitus rating recovered to basal values after two days. Two patients (47; n s = 26) failed to complete the study due to worsening of tinnitus after LF stimulation of the left auditory cortex (LAC). The same study reported a common complaint of transient tinnitus increase during active stimulation. In the last LF rTMS study reporting tinnitus exacerbation (114; n = 14), two patients reported a worsening of tinnitus after rTMS to the tempoparietal junction (TPJ), however the details of this worsening are not reported possibly due to the author's classification of this adverse event as "moderate."
With theta burst stimulation (TBS) to the LTC, three patients (119; n s = 33) complained of worsening tinnitus after their first experience with one of three TBS protocols. A single patient, (116; n s = 14), had an increase in tinnitus lasting for two weeks following one day of 10 Hz rTMS at various scalp locations. Three patients (101; n s = 10) reported a very loud tinnitus after individual alpha frequency (IAF) rTMS, which lasted for several hours up to a few days.
The combined HF and LF rTMS study (99; n s = 13), reports one patient experiencing aggravated tinnitus symptoms immediately after stimulation and lasting for 10 days. The rTMS protocol utilized a brief 10 Hz pulse followed by longer 1Hz stimulation. The rTMS target was posterior to the fMRI determined auditory cortex. This patient completed the entire study.
Among migraine publications, there was one (98; n s = 102), which reported three patients experiencing migraine during or following treatment of LF rTMS over occipital cortex. One of these migraine attacks was considered severe, however relevant details are not provided in the text. d) Other adverse events-271 out of 1815 patients reported adverse events other than seizure or primary symptom aggravation, which are listed in Table 9 . This translates into a 14.93% (95% CI: 13.29 -16.57%) crude risk for the remaining symptoms. The majority of adverse events (208 out of 271 reported) were noted in tinnitus and AH groups. e) Adverse events during placebo rTMS-Of the 67 publications (n s = 1275) in which included a placebo condition, there were 67 out of 1275 subjects that reported adverse events. This equates to a 5.25% (95% CI: 4.03 -6.47%) crude risk for adverse events in the placebo rTMS condition. The most severe adverse event reported was deterioration of psychological clinical state in 3 patients (64,75), which carries a crude risk of 0.23% (95% CI: 0 -0.49%). The second most severe adverse event, symptom exacerbation, was reported in two AH studies (13, 75 ; n s = 12, n s = 23). Another report (47) indicated an increase in tinnitus in some patients, but the number of subjects for this adverse event was not quantified. The most common adverse event was headache in 24 out of 1275 patients, equating to a crude risk of 1.88% (95% CI: 1.13 -2.63%). A single study (114) did not clarify which adverse events corresponded to placebo or real rTMS.
Discussion
The published data suggest that rTMS is generally well tolerated in patients with positive sensory symptoms. Seizure, the most serious reported adverse event was rare, occurring only in three of 1815 subjects: in one during LF rTMS for tinnitus and two during HF rTMS for chronic pain (Table 8 ; 111,113,122). However that the data for patients experiencing seizure during rTMS are derived from two case reports and one larger treatment trial, and should be interpreted with caution. In particular there is published debate as to whether one of the cases (111), an instance of seizure during LF rTMS in a patient with tinnitus, was indeed seizure or convulsive syncope (147,149). Previous surgical intervention in one patient (122) or concurrent use of antidepressant and anticonvulsant medication in another (113) should also be considered important risk factors for increased seizure risk.
We note that 27 case reports are included in our safety review, of which only eight report the occurrence of unwanted side effects (71, 76, 89, 111, 122, 136, 138, 144) . This was necessary as two out three instances of seizure in this patient population were reported in case report form. (111,122) . The reader should recognize that inclusion of case reports may skew metanalysis results towards a higher proportion of adverse events, and should be interpreted with caution. For instance, three out of 25 reports were published explicitly to describe an adverse event occurrence: either seizure (n s = 2) or increased "passivity" (n s = 1) (111,122,136).
Although statistically sound conclusions cannot be made from these limited data, the likelihood of seizure induction by rTMS in patients with positive sensory symptoms may approximate that of the general population. According to a review of the literature incorporated into the 2009 TMS application guidelines, the risk of seizure in healthy subjects is <1% with either LF rTMS or HF rTMS (44) . With the conservative assumption that all three reported instances were indeed seizures induced by rTMS, the crude per subject risk in this group also appears <1% (0.08% (95% CI: 0 -0.24%) for LF rTMS and 0.25% (95% CI: 0 -0.59%) for HF rTMS). In contrast, patients with epilepsy have a considerably greater likelihood of seizure induction during rTMS (>1.4%) (14, 28) . Thus, although alterations in regional cortical excitability may predispose patients with positive sensory symptoms toward seizures, the published data do not support a markedly heightened risk relative to other disease states (44, 45, 145) .
Along similar lines as seizure induction in patients with epilepsy, positive sensory symptom exacerbation is another theoretical adverse effect of rTMS in the studied patient population. As these syndromes are associated with pathologic alterations in regional cortical activity, modulation of cortical excitability induced by rTMS may theoretically alter how the patient perceives his or her symptom. However, here also, the risk of symptom exacerbation appears to be relatively low 1.16% (95% CI: 0.61 -1.71%). There were several studies in which aggravation of disease state was described, but was not classified as an adverse event (47,89,90,125,128).
It is interesting to point out that in several studies an increase in tinnitus was reported as an adverse event, however its increase was not durable (47,62,89,91,116,117,119,125). In addition, this symptom exacerbation would sometimes be preceded a significant reduction in tinnitus severity (47,62,89,125). In cases reporting dropouts, patients never made it past the two-day increase that was described. It may be that the auditory cortex has an inherent threshold for activation that must be reached before stimulation becomes of therapeutic benefit.
It is worth considering that neurologic rTMS effect may result from an interaction between applied current and ongoing brain activity. Thus, in cases of seizure or symptom exacerbation following rTMS in patients with positive sensory phenomena, state dependent effect of rTMS might be playing an important role (151). In patients with positive sensory phenomena, the targeted cortical may be characterized either by abnormal excitability or abnormal plasticity, and this will condition the effects of rTMS. Thus, the effects might be opposite, in part due to metaplasticity mechanisms.
Pharmacotherapy is another important confounding factor that can contribute to the likelihood of adverse events during rTMS. While the disease state provides an initial change in the cortical steady state activity, the introduction of drugs either past or present can have a lasting impact on cortical activity and simultaneously alter the effect of rTMS.
Upon examining adverse effects other than seizure or symptom exacerbation, we find that the type and frequency of minor of adverse events are similar to rTMS studies on other neuropsychiatric disorders (54,145,146,148,150). In our review these additional adverse events were reported most often in AH studies, followed by tinnitus and were less frequently observed in neuropathic pain and migraine (with only two VH and fibromyalgia cases published, an absence of reported adverse events is of little statistical value). This may be attributed to distinct pathophysiology of these symptoms. However, discrepancy in the apparent rate of adverse events may also reflect differences in experimental design, symptom surveys, or underreporting of adverse events that are considered less severe than seizure. It is important to highlight that future prospective trials characterizing rTMS safety and tolerability should incorporate detailed questionnaires, which may capture, in greater detail, symptoms other than those relating to the chief complaint. Particularly, among plausible adverse events, loss (or lack thereof) of normal function is not regularly mentioned in rTMS clinical literature, and necessitates inclusion in adverse events records of future trials.
Side effects were more frequent in active stimulation versus the placebo condition, 16.7% to 5.25%. In particular there was no report of seizure with placebo stimulation. However, the range of adverse events was the similar to active stimulation, including aggravation of positive sensory symptoms, but excluding seizure occurrence. The published data are lacking a consistent controlled experimental design, and consistent report reporting of adverse events during sham rTMS.
As rTMS gains acceptance in management of neuropsychiatric symptoms, further studies of its safety will be necessary. The published data to date support that in appropriate circumstances the risk:benefit ratio may favor rTMS use for treatment of symptoms characterized by positive sensory phenomena and likely regional cortical hyperxcitability, but certainly warrants further investigation. It is the suggestion of these authors that all reports include a section indicating presence or lack of adverse events and all pertinent details. In particular, reports of seizure and symptom exacerbation make the case for future studies aimed to characterize the overall safety and tolerability of a treatment paradigm, which has the potential to alter cortical excitability. This improvement was less in 20 days, but upon follow-up the reduction in AH was markedly more as compared to 10 days of treatment.
Table 2
Literature review summary of tinnitus treatment or investigation by rTMS
Note all studies used a Figure Occiput just below the occipital bone, location method not specified.
No Sham Coil
Headache (n = 3) Migraine (n = 3) Sinusitis (n = 2)
Optic neuritis (n = 1) Nausea (n = 1)
Self-reporting • GTC (initial tonic phase for 8 seconds, followed by clonic movements for about 3 min).
• Heart rate elevation.
• No incontinence.
• 10 min postictal confusion.
• Complete amnesia for event.
• Oxygenation was provided and intravenous medication access was achieved but occurred after seizure had ended.
• Seizure occurred on the 5th day of stimulation during the 10th session. • Mild post-ictal confusion lasting 15 minutes.
• Following seizure there were no motor deficits, head CT and EEG were normal.
• Table 9 rTMS adverse events by positive sensory symptom Number of patients experiencing specified adverse events per positive sensory symptom. Total number patients with adverse event are given along with corresponding percentage of total patient population within positive sensory symptom. 
